ENDORECTAL
MAGNETIC RESONANCE IMAGING IN PERSISTENT HEMOSPERMIA
(
Download pdf )
ADILSON PRANDO
Department
of Radiology and Diagnostic Imaging, Vera Cruz Hospital, Campinas, Sao
Paulo, Brazil
ABSTRACT
Objective:
To present the spectrum of abnormalities found at endorectal magnetic
resonance imaging (E-MRI), in patients with persistent hemospermia.
Materials and Methods: A review of E-MRI
findings observed in 86 patients with persistent hemospermia was performed
and results compared with those reported in the literature. Follow-up
was possible in 37 of 86 (43%) patients with hemospermia.
Results: E-MRI showed abnormal findings
in 52 of 86 (60%) patients with hemospermia. These findings were: a) hemorrhagic
seminal vesicle and ejaculatory duct, isolated (n = 11 or 21%) or associated
with complicated midline prostatic cyst (n = 10 or 19.0%); b) hemorrhagic
chronic seminal vesiculitis, isolated (n = 14 or 27%) or associated with
calculi within dilated ejaculatory ducts (n = 2 or 4 %); c) hemorrhagic
seminal vesicle associated with calculi within dilated ejaculatory duct
(n = 4 or 7.7%) or within seminal vesicle (n = 4 or 7.7%); d) non-complicated
midline prostatic cyst (n = 6 or 11.5%); and e) prostate cancer (n = 1
or 2%). Successful treatment was more frequent in patients with chronic
inflammatory and/or obstructive abnormalities.
Conclusion: E-MRI should be considered the
modality of choice, for the evaluation of patients with persistent hemospermia.
Key
words: hemospermia; diagnostic imaging; magnetic resonance imaging
Int Braz J Urol. 2008; 34: 171-9
INTRODUCTION
Hemospermia
or hematospermia is not an uncommon clinical urological problem among
adult men, but its exact prevalence remains unknown. Hemospermia is prevalent
in young males with a mean age of 37 years (1-5). Urogenital inflammation
and infection are usually considered the most common cause of hemospermia
in this group of patients. In young males often only simple, tailored
investigations and appropriate treatment are required. In older patients,
above 40 years of age, or those with recurrent hemospermia or associated
symptoms, other benign causes and rarely malignancy can be found (5,6).
Imaging evaluation of patients with recurrent
hemospermia is usually performed by transrectal ultrasound (TRUS) (7-10).
In contrast to TRUS, endorectal magnetic resonance imaging (E-MRI) has
the ability to identify hemorrhage within the reproductive structures,
but despite its superior diagnostic capability there are only few reports
describing its utility in the assessment of persistent hemospermia (10-12).
Our aim was to illustrate the spectrum of
abnormalities found at E-MRI in patients with persistent hemospermia.
MATERIALS
AND METHODS
Between
March 2000 and May 2007, 86 consecutive patients with persistent hemospermia
of an average duration of 16.7 months (range, 6-48 months), underwent
E- MRI at our institution. Mean patient age was 37 years (range, 25-72
years). Sixty patients (70%) were asymptomatic except for hemospermia.
One or more associated symptoms, laboratorial or clinical findings were
obtained in the remaining 26 patients (30%): frequency or urgency (n =
10), perineal discomfort or pain (n = 8), ejaculatory pain (n = 4), arterial
hypertension (n = 2) and hematuria (n = 2). After treatment follow-up
was obtained in 37 patients. Conventional MR imaging was performed with
a 1.5-T MR imager (Signa; GE Medical Systems, Milwaukee, WI.). Patients
were examined by using the body coil for signal acquisition and a combination
of a pelvic phased-array coil (; GE Medical Systems, Torso PA) with a
commercially available balloon-covered endorectal coil (Endo ATD; Medrad,
Pittsburgh, PA.), for signal reception. The balloon-covered endorectal
coil was inflated with 90 mL of liquid perfluorocarbon (12). On MR images,
the prostate was evaluated with transverse spin-echo T1-weighted MR images
by using the following parameters: repetition time msec/echo time msec,
575/minimum; section thickness, 3 mm; matrix, 256 x 224; two signals acquired;
field of view, 13 cm; intersection gap, 0 mm; bandwidth, 20.83 kHz. Transverse
and transverse-oblique T2-weighted images were obtained with the following
parameters: 3500/130, section thickness, 3 mm; matrix, 256 x 224, three
signals acquired; field of view, 13 cm; intersection gap, 0 mm; bandwidth,
20.83 kHz. For the transverse images, phase encoding was in the right-to-left
direction. T2-weighted sagittal MR images were obtained with the following
parameters: 4000/150; section thickness, 5 mm; matrix, 256 x 192; two
signals acquired; field of view, 15 cm; intersection gap, 2 mm; bandwidth,
41.67 kHz. For the T2-weighted sagittal MR images, phase encoding was
in the superior-to-inferior direction. After treatment follow-up was possible
in 37 of 86 (43%) patients.
RESULTS
In
patients with hemospermia, E-MRI showed abnormal findings in 52 out of
the 86 patients (60%). Hemorrhage within the seminal vesicle or the ejaculatory
duct was recognized in 45 of 86 patients (52 %). Blood within seminal
vesicle or ejaculatory duct appears as areas of high signal intensity
on T1-weighted spin-echo images representing the presence of metahemoglobin
due to subacute hemorrhage (12).
The imaging criteria used to characterize
seminal vesiculitis were: diffuse wall thickening of the seminal vesicle
with low T2-weighted signal intensity, loss of convolutions and proteinaceous
or hemorrhagic fluid content with variable signal intensity on T1-weighted
and T2-weighted images(10). Thus, significant abnormal E-MRI findings
observed in this group of patients were: a) hemorrhagic seminal vesicle
and ejaculatory duct, isolated (n = 11 or 21%) or associated with complicated
midline prostatic cyst (n = 10 or 19.0%) (Figure-1); b) hemorrhagic chronic
seminal vesiculitis, isolated (n = 14 or 27%) (Figure-2) or associated
with calculi within dilated ejaculatory ducts (n = 2 or 4 %); c) hemorrhagic
seminal vesicle associated with calculi within dilated ejaculatory duct
(n = 4 or 7.7%) or within seminal vesicle (n = 4 or 7.7%) (Figure-3);
d) non-complicated midline prostatic cyst (n = 6 or 11.5%); and e) prostate
cancer (n = 1 or 2%), Figure-4.
Thirteen patients with hemospermia underwent
transurethral endoscopic treatment (unroofing of the midline cysts or
ductal obstruction and resection, fulguration, and dilatation of ejaculatory
duct obstruction). This approach was successful in 5 patients with dilated
hemorrhagic seminal vesicle(s) and ejaculatory duct associated with complicated
midline prostatic cyst; in 4 patients with hemorrhagic seminal vesiculitis
and calculus within dilated ejaculatory duct and in 1 patient with non-complicated
midline prostatic cyst. The same procedure was unsuccessful in 3 patients
with non-complicated midline prostatic cyst. Hemospermia disappeared completely
in 9 out of 12 patients following an E-MRI diagnosis of hemorrhagic chronic
seminal vesiculitis and subsequent antimicrobial and or anti-inflammatory
drugs. Spontaneous elimination of a seminal vesicle calculus was reported
by one patient with complete remittance of the hemospermia. Two patients
suspected to have prostate cancer due to the presence of focal hypointense
area on T2-weighted images, in the peripheral zone of the prostate, were
further evaluated with TRUS-guided biopsy guided by magnetic resonance
imaging findings (13). This technique allowed the diagnosis of cancer
in only one of these patients.
COMMENTS
Although
hemospermia is usually a benign and self-limiting condition, it provokes
great concern and anxiety in sexually active patients. Hemospermia may
be secondary to inflammation, infection, ductal obstruction or cysts,
benign neoplasm, vascular abnormalities, systemic or iatrogenic factors
and rarely malignant tumors. History and physical examination are often
unrevealing (1). In patients younger than 40 years an infective cause
in the urogenital tract is the most common etiological factor (5). Factors
that dictate the extent of investigation are patient age, the duration
of hemospermia, whether it is persistent and the presence of associated
symptoms or signs such as weight loss, local or bony pain, fever, lower
urinary tract symptom and hematuria. It is widely accepted that persistent
hemospermia or hemospermia with an associated symptom and hemospermia
in older patients requires more extensive investigation (1-9).
In our small series of patients, laboratorial
or clinical findings were present in 26 out 86 patients(30%): frequency
or urgency (n = 10), perineal discomfort or pain(n = 8), ejaculatory pain
(n = 4), arterial hypertension (n = 2) and hematuria (n = 2). Both patients
with hematuria with normal E-MRI findings were submitted to direct rigid
and flexible cystoscopy. Papillary urethritis was found in one patient.
TRUS can be considered a safe, noninvasive
and relatively inexpensive method, which allows clear images of the reproductive
system structures. TRUS has an accurate diagnostic rate of between 74%
and 95% for the evaluation of hemospermia (5). E-MRI has superior imaging
capability since offers higher spatial resolution for the visualization
of the whole seminal tract. E-MRI allows the demonstration of normal variations;
presence of hemorrhage and evident signs of chronic infection, obstruction
and malignancies. Contrary to TRUS, MRI has the ability to accurately
identify hemorrhage within the seminal tract due to its characteristic
signal behavior (high signal intensity on T1-weighted images).
Imaging studies have considered a wide range
of etiological factors for hemospermia: prostatic calcification, prostatic
hypertrophy, prostatitis, midline prostatic cyst (utricular), midline
extra-prostatic cyst, seminal vesicle cyst or calculi, dilatation of the
seminal vesicles or the ejaculatory ducts, ejaculatory duct cyst, blood
within normal or thick-walled seminal vesicle (seminal vesiculitis) or
the ejaculatory duct, seminal vesicle amyloidosis, periprostatic varicosities
and prostatic carcinoma (5-11,13-17).
Some of these abnormalities such as prostatic
hypertrophy, dilatation of the seminal vesicle(s), prostatic calcification
and non-complicated midline prostatic cyst, can be found in asymptomatic
patients. Seminal vesicle(s) dilatation for example, has been described
as a very common cause of hemospermia (9,12,14) but it is known that various
filling states of the seminal vesicles are quite normal. For this reason,
we are speculating that perhaps there is a tendency to consider many incidental
and common urological abnormalities as the etiological factor of hemospermia
(14,18,19). This could possibly explain why the success rate of the treatment
was variable in our small series of patients. Transurethral endoscopic
treatment was more effective in patients with clear obstructive findings
and failed in 3 patients with non-complicated, non obstructive, midline
prostatic cyst. This mechanism could also explain why therapy with antimicrobial
and or anti-inflammatory drugs was more effective in patients with evident
manifestation of seminal vesiculitis and failed in the majority of patients
with hemorrhagic seminal vesicle. Although the lack of histological confirmation
of chronic seminal vesiculitis (no seminal vesicle biopsy) is a limitation
of our study, we may assume that our imaging criteria for chronic seminal
vesiculitis is correct since in most of the patients with this MRI findings,
hemospermia disappeared after adequate antimicrobial/anti-inflammatory
treatment.
In conclusion, E-MRI should be considered
the modality of choice for the evaluation of patients with persistent
hemospermia. In our series, the most significant E-MRI findings were:
hemorrhagic seminal vesicle and ejaculatory duct, isolated or associated
with complicated midline prostatic cyst; hemorrhagic chronic seminal vesiculitis,
isolated or associated with calculi within dilated ejaculatory ducts,
hemorrhagic seminal vesicle associated with calculi within dilated ejaculatory
duct or within seminal vesicle, non-complicated midline prostatic cyst
and prostate cancer. Successful treatment was, in fact, more frequent
in patients with chronic inflammatory and/or obstructive abnormalities.
CONFLICT
OF INTEREST
None
declared.
REFERENCES
- Munkel witz R, Krasnokutsky S, Lie J, Shah SM, Bayshtok J, Khan SA:
Current perspectives on hematospermia: a review. J Androl. 1997; 18:
6-14.
- Ameur A, Touiti D, Jira H, el Alami M, Boumdin H, Abbar M: Hemospermia:
diagnosis and therapeutic aspects. Seven case reports. Ann Urol (Paris).
2002; 36: 74-80.
- Fletcher MS, Herzberg Z, Pryor JP: The aetiology and investigation
of haemospermia. Br J Urol. 1981; 53: 669-71.
- Mulhall JP, Albertsen PC: Hemospermia: diagnosis and management.
Urology. 1995; 46: 463-7.
- Ahmad I, Krishna NS: Hemospermia. J Urol. 2007; 177: 1613-8.
- Han M, Brannigan RE, Antenor JA, Roehl KA, Catalona WJ: Association
of hemospermia with prostate cancer. J Urol. 2004; 172: 2189-92.
- Worischeck JH, Parra RO: Chronic hematospermia: assessment by transrectal
ultrasound. Urology. 1994; 43: 515-20.
- Etherington RJ, Clements R, Griffiths GJ, Peeling WB: Transrectal
ultrasound in the investigation of haemospermia. Clin Radiol. 1990;
41: 175-7.
- Yagci C, Kupeli S, Tok C, Fitoz S, Baltaci S, Gogus O: Efficacy of
transrectal ultrasonography in the evaluation of hematospermia. Clin
Imaging. 2004; 28: 286-90.
- Torigian DA, Ramchandani P: Hematospermia: imaging findings. Abdom
Imaging. 2007; 32: 29-49.
- Weintraub MP, De Mouy E, Hellstrom WJ: Newer modalities in the diagnosis
and treatment of ejaculatory duct obstruction. J Urol. 1993; 150: 1150-4.
- Lencioni R, Ortori S, Cioni D, Morelli G, Ceretti E, Cosottini M,
et al.: Endorectal coil MR imaging findings in hemospermia. MAGMA. 1999;
8: 91-7.
- Prando A, Kurhanewicz J, Borges AP, Oliveira EM Jr, Figueiredo E:
Prostatic biopsy directed with endorectal MR spectroscopic imaging findings
in patients with elevated prostate specific antigen levels and prior
negative biopsy findings: early experience. Radiology. 2005; 236: 903-10.
- Maeda H, Toyooka N, Kinukawa T, Hattori R, Furukawa T: Magnetic resonance
images of hematospermia. Urology. 1993; 41: 499-504.
- Garcia NR, Gozales IF, Mateo CP, Castro GE, Tello AM: Hematospermia
y quiste del conducto mülleriano. Arch Esp Urol. 2005; 58: 1061-4.
- Fuse H, Sumiya H, Ishii H, Shimazaki J: Treatment of hemospermia
caused by dilated seminal vesicles by direct drug injection guided by
ultrasonography. J Urol. 1988; 140: 991-2.
- Furuya S, Kato H: A clinical entity of cystic dilatation of the utricle
associated with hemospermia. J Urol. 2005; 174: 1039-42.
- Ishikawa M, Okabe H, Oya T, Hirano M, Tanaka M, Ono M, et al.: Midline
prostatic cysts in healthy men: incidence and transabdominal sonographic
findings. AJR Am J Roentgenol. 2003; 181: 1669-72.
- Curran S, Akin O, Agildere AM, Zhang J, Hricak H, Rademaker J: Endorectal
MRI of prostatic and periprostatic cystic lesions and their mimics.
AJR Am J Roentgenol. 2007; 188: 1373-9.
____________________
Accepted after revision:
February 25, 2008
_______________________
Correspondence address:
Dr. Adilson Prando
Av. Andrade Neves, 707
Campinas, SP, 13013-161, Brazil
Fax: + 55 19 3231-6629
E-mail: aprando@mpc.com.br
EDITORIAL COMMENT
Hemospermia
can be considered a challenging situation for both urologists and radiologists,
given its relatively high prevalence and poor understanding. Transrectal
ultrasound, despite being a good modality for prostate evaluation and
guided-intervention, has limited applications for dedicated seminal vesicles
imaging, especially regarding identification of blood within the ducts
(1). The article from Dr. Prando confirms the evolving role of Magnetic
Resonance Imaging (MRI) in the evaluation of hemospermia and other seminal
vesicles diseases, since it combines high spatial resolution with outstanding
contrast resolution (the ability to characterize different structures
and components, like blood). Endorectal MRI is now considered the modality
of choice for local staging of prostate cancer, including seminal vesicles
invasion (2). The development and increasing availability of 3 Tesla MR
scanners can further improve the application of this imaging modality
in the evaluation of the seminal vesicles, since its intrinsic high signal
intensity might exempt the need for an endorectal coil (3). Nowadays,
regardless these specific technological aspects, we can confidently state
that MRI is the imaging modality of choice for evaluation of hemospermia
and other seminal vesicles diseases.
REFERENCES
- Cho IR, Lee MS, Rha KH, Hong SJ, Park SS, Kim MJ: Magnetic resonance
imaging in hemospermia. J Urol. 1997; 157: 258-62.
- Wang L, Hricak H, Kattan MW, Chen HN, Kuroiwa K, Eisenberg HF, et
al.: Prediction of seminal vesicle invasion in prostate cancer: incremental
value of adding endorectal MR imaging to the Kattan nomogram. Radiology.
2007; 242: 182-8.
- Sosna J, Pedrosa I, Dewolf WC, Mahallati H, Lenkinski RE, Rofsky
NM: MR imaging of the prostate at 3 Tesla: comparison of an external
phased-array coil to imaging with an endorectal coil at 1.5 Tesla. Acad
Radiol. 2004; 11: 857-62.
Dr.
Ronaldo Hueb Baroni
Radiologist, Body Imaging Department
Institute of Radiology, USP and
Albert Einstein Israelita Hospital
São Paulo, SP, Brazil
E-mail: rbaroni@einstein.br
EDITORIAL COMMENT
In
his paper published in this issue of the International Brazilian Journal
of Urology, Prando presents an overview of abnormalities found at endorectal
coil magnetic resonance imaging (MRI) in patients with persistent hemospermia.
The use of MRI instead of imaging modalities
such as transrectal ultrasonography or computed tomography seems quite
evident. Magnetic resonance imaging allows direct multiplanar image acquisition
and offers superb soft tissue contrast, enabling accurate depiction and
characterization of soft tissues within the pelvis and facilitating the
demonstration of blood products within the male reproductive system. When
combined with an endorectal coil, the image resolution can be further
increased, providing unsurpassed image detail of the prostate gland, ejaculatory
ducts and seminal vesicles. Hence, Prando found abnormalities that were
directly related to hemospermia in about 60% of cases.
On the other hand, uncomplicated hemospermia
usually has only minor clinical significance and needs no immediate imaging
evaluation, especially in younger patients (less than 40 years of age).
However, in cases of persistent or complicated hemospermia, it can be
very disquieting for patients and frustrating for urologists to have no
information about the location or the etiology of the bleeding. So far,
transrectal ultrasonography has been the examination of first choice in
these patients. It is a relatively inexpensive and readily available technique
that allows the identification of benign prostatic hyperplasia, dilated
ejaculatory ducts or seminal vesicles, and obvious lithiasis, cystic lesions,
or tumors. On the other hand, transrectal ultrasound cannot directly prove
the presence of blood products within the ejaculatory ducts or seminal
vesicles and will fail to disclose more subtle abnormalities. Although
computed tomography (CT) can readily demonstrate the presence of calcifications
and high-density blood within the seminal ductal system, its diagnostic
application is hampered because of its low tissue discriminating ability
(all structures in and around the prostate and seminal vesicles have about
the same density, and also contrast-enhancement is not usually helpful),
and because of its radiation exposure, which is not trivial in the younger
patient group. MRI does not suffer from the abovementioned inconveniences.
We strongly believe, however, that in the
majority of patients with hemospermia no immediate imaging evaluation
is required. Furthermore, transrectal sonography remains a valid and readily
accessible primary technique to disclose more obvious abnormalities of
the prostatovesicular complex. However, in complicated or persistent hemospermia,
certainly in patients above 40 years of age, MRI may have the potential
to disclose more subtle abnormalities that remain obscure on transrectal
ultrasonographic examination. Although we are currently not aware of any
study having directly compared the diagnostic value of transrectal ultrasound
with that of MRI, it is not unreasonable to expect that MRI might become
the imaging modality of first choice to evaluate patients with persistent
or complicated hemospermia.
Dr.
Geert M. Villeirs &
Dr. Willem Oosterlinck
Dept of Radiology (GMV) and Urology (WO)
Ghent University Hospital
Gent, Belgium
E-mail: geert.villeirs@ugent.be
EDITORIAL COMMENT
I
read with great interest the article by Dr. Prando in which he evaluates
findings of endorectal magnetic resonance (E-MRI) in patients with persistent
hemospermia. Although in the majority hemospermia is a benign and self-limiting
condition, the question lies in how to investigate these patients. To
date, a small number of studies using an endorectal coil for evaluation
of patients with hematospermia have been published. Magnetic resonance
is the current gold standard for imaging the accessory sex glands and
their ducts and, E-MRI promotes an excellent multiplanar anatomic evaluation
of the prostate gland, seminal vesicles and ejaculatory ducts. However,
we know that transrectal ultrasonography (TRUS) is an effective and widely
used technique as a primary modality for patients with hemospermia. TRUS
can also detect dilatation, cysts and stones in the seminal vesicles,
prostate and ejaculatory ducts. The greatest advantage of E-MRI over TRUS
is its ability to reveal hemorrhage in the seminal vesicles or prostate.
I also agree that Dr. Prando imaging criteria for chronic seminal vesiculitis
is by far superior to those that we can infer by using TRUS. Probably,
the addition of contrast gadolinium further improves resolution of magnetic
resonance for inflammatory signs.
Infective cause in the urogenital tract
is the most common etiological factor. Dr. Prando confirms findings of
inflammatory conditions as a common association with hemospermia and this
is demonstrated in recent studies where current laboratory techniques
detected a pathogen in 75% of cases of hemospermia (1).
In summary, current evidence suggests that,
for patients with persistent hemospermia, endorectal coil MRI should be
performed when TRUS is unsatisfactory or nondiagnostic.
REFERENCE
- Bamberger E, Madeb R, Steinberg J, Paz A, Satinger I, Kra-Oz Z, et
al.: Detection of sexually transmitted pathogens in patients with hematospermia.
Isr Med Assoc J. 2005; 7: 224-7.
Dr.
Nelson M. G. Caserta
Dept. of Radiology,
Unicamp State University of Campinas
Campinas, SP, Brazil
E-mail: ncaser@mpcnet.com.br |